Preclinical, Clinical Drug-Eluting Stent Trial Insights Provided By FDAers
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent manufacturers should adopt robust test methods for replicating failure rates observed in animal models, according to CDRH Division of Cardiovascular Devices Biomedical Engineer Jonette Foy